Competitive Technologies, Inc. (NYSE Amex:CTT) today announced the presentation of results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment. A three-hour discussion led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, at the American Society of Clinical Oncology (ASCO) Annual Meeting, cited results of the study. In a second venue at the ASCO meeting, Charles L. Loprinzi, M.D. Regis Professor of Breast Cancer Research in the Mayo Clinic's Division of Medical Oncology, presented Dr. Smith's research. The presentations highlighted the conclusion of the Massey Cancer Center study, that "Patient-specific cutaneous electrostimulation with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity."
Calmare, which treats chronic neuropathic and oncologic pain, received FDA certification for sales in the U.S. in 2009. In June 2009, clinical investigators at the VCU Massey Cancer Center began the first U.S. independent clinical study, to specifically examine the ability of CTT's Calmare pain therapy treatment to decrease pain associated with CIPN.
"The Massey Cancer Center team, led by Dr. Smith, was the first independent group in the U.S. to conduct its own evidence-based study using the Calmare pain therapy device to treat CIPN in cancer patients. CIPN is a very debilitating side effect for some 30-40 percent of cancer patients, causing sharp pain in their hands and feet. CIPN affects cancer patients worldwide, including an estimated 4 million cancer patients in the U.S. Calmare pain therapy is the only highly effective treatment for CIPN without the harmful, adverse side effects of opioids," said John B. Nano, CTT's Chairman, President and CEO. "Finding new, non-invasive ways to treat pain other than prescribing opioids such as morphine is a key focus of our mission to improve the quality of life for cancer patients. We expect to create a paradigm shift in how chronic pain is treated globally, which impacts over 75 million in the U.S. alone."
Conclusions from the ASCO presentations are as follows:
- MC5-A Calmare therapy relieved refractory CIPN pain quickly and significantly, with minimal side effects.
- Some pain relief is durable for months but some requires retreatment and maintenance.
- 4 of 16 had complete disappearance of pain.
- Patients experienced a 64% reduction in pain.
- Some patients had return of complete or partial normal sensation, and relief of numbness, as well as relief of pain.
For more information on the ASCO presentations, visit www.calmarett.com.